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Abstract 
Background: Etanercept is a fully human tumor necrosis factor α receptor fusion protein 
that binds tumor necrosis factor α with greater affinity than natural receptors. Biologics 
are widely used in the treatment of psoriasis and psoriasis arthritis and may represent a 
new therapeutic option for some patients with psoriatic nail disease.  
Case Report: We report a case of lichen planus limited to the toe nails successfully 
treated with etanercept monotherapy.  
Conclusion: The significant improvement of our case suggests that etanercept is an 
effective treatment modality for lichen planus limited particularly to the nails. Further 
controlled studies are needed to establish the effectiveness and therapeutic regimes. 
 
Introduction 
Lichen planus (LP) is an inflammatory skin disorder with great polymorphism of its 
clinical appearance. Nail involvement occurs in 10% of patients with disseminated disease 
and may also develop in the absence of cutaneous symptoms as a destructive 
inflammatory onychodystrophy [1]. Treatment of nail LP is difficult and disappointing. 
Biological therapies are now widely used for moderate to severe chronic plaque psoriasis 
and psoriasis arthritis. A number of recent reports have been published on the use of 
biologics such as tumor necrosis factor (TNF)-antagonists (e.g. etanercept [2], infliximab 
[3, 4]) as new therapeutic option for psoriatic nail disease.  
Case Report 
A 53-year-old Caucasian woman was referred to our department for evaluation of onychodystrophy 
involving multiple fingers and toe nails. The painful nail changes had progressively appeared over the 
past 5 years and were extremely disabling in daily living activities. Except for an atopic constitution with 
chronic eczema and seasonal allergic rhinoconjunctivitis, her past medical history was noncontributory 
and she was not on any regular systemic medication. Clinical examination of the affected nails showed  
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onychodystrophy, discoloration, subungual hyperkeratosis as well as some longitudinal ridging, 
striation, splitting and thinning (fig. 1). The diagnosis of nail LP was made based on these clinical 
features. The patient had no other evidence of skin or mucosal involvement of LP or psoriasis. Since 
several topical treatments, including potent topical steroids, topical cyclosporine, tazarotene cream and 
systemic retinoids, had been ineffective, treatment with systemic cyclosporine 250 mg/day (3 mg/kg 
body weight) was initiated, which lead to significant improvement of most nails. However, since the 
patient developed arterial hypertension, treatment with cyclosporine was discontinued after 3 years. A 
relapse particularly of her toe nails occurred within a few weeks. Therapy with etanercept (25 mg s.c. 
twice weekly for the first 6 months and 50 mg s.c. once weekly thereafter) was then initiated, which 
again lead to a marked improvement of her toe nail lesions within 6–9 months (fig. 2). Therapy was well 
tolerated with no side-effects. 
Discussion 
LP is considered to be a T-cell mediated autoimmune skin disease, in which 
autoreactive CD8+ cytotoxic T lymphocytes are key effectors through the induction of 
keratinocyte lesions [5]. There is one report of a patient with refractory oral and 
cutaneous LP who experienced significant improvement after therapy with efalizumab 
[6]. Another report on the use of alefacept in two patients with LP showed a dramatic 
response of all skin lesions [7]. Etanercept is a fully human TNF-α receptor fusion protein 
that binds TNF-α with greater affinity than natural receptors. It is approved for the 
treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, 
psoriasis and psoriasis arthritis in the USA, Canada and Europe. One case of severe 
erosive LP was reported to be improved by etanercept [8]. On the other hand, a case of LP 
occurring during etanercept therapy for rheumatoid arthritis was described, indicating 
that anti-TNF-α therapy may also be associated with the paradoxical induction of 
inflammatory disease such as psoriasis eruptions [9]. 
The significant improvement of our case suggests that etanercept is an effective 
treatment option for LP limited to the nails. Further controlled studies are warranted to 
determine more accurately both the effectiveness and therapeutic regimes of etanercept in 
this indication. 
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Fig. 1. Clinical features at presentation. 
 
 
 
Fig. 2. Clinical findings of the patient before (a), 3 months (b) and 9 months (c) after etanercept 
monotherapy (25 mg s.c. twice weekly for the first 6 months and 50 mg s.c. once weekly thereafter). 
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